Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors

被引:28
作者
Ward, RA
Perkins, TDJ
Stafford, J
机构
[1] AstraZeneca, Canc Discovery, Macclesfield SK10 4TG, Cheshire, England
[2] AstraZenecaR&D Molndal, S-43183 Molndal, Sweden
关键词
D O I
10.1021/jm0505866
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Structure-based virtual screening was performed against the target dipeptidyl peptidase IV (DPP-IV) to identify good chemical starting points for medicinal chemistry. A database of available compounds was filtered by calculated physical properties and undesired chemistry. This database was matched against two in-house designed DPP-IV pharmacophores, and the hits from these pharmacophore searches were docked into a DPP-IV crystal structure. Compounds were then selected for testing and 51 active compounds were identified from a list of 4000 compounds tested. These had activities ranging from 30% to 82% when tested at a concentration of 30 mu M in an enzyme inhibition assay.
引用
收藏
页码:6991 / 6996
页数:6
相关论文
共 34 条
[31]  
Villhauer E. B., 1998, [No title captured], Patent No. [09819998, WO9819998, 9819998]
[32]   1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties [J].
Villhauer, EB ;
Brinkman, JA ;
Naderi, GB ;
Burkey, BF ;
Dunning, BE ;
Prasad, K ;
Mangold, BL ;
Russell, ME ;
Hughes, TE .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (13) :2774-2789
[33]   Large-scale virtual screening for discovering leads in the postgenomic era [J].
Waszkowycz, B ;
Perkins, TDJ ;
Sykes, RA ;
Li, J .
IBM SYSTEMS JOURNAL, 2001, 40 (02) :360-376
[34]  
Wenslow R. M, 2005, WO Patent, Patent No. [WO2005020920 (A2), 2005020920, 2005/ 020920]